Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, United States; Department of Obstetrics and Gynecology, Mount Sinai Hospital, New York, NY, United States.
Contraception. 2021 May;103(5):367-370. doi: 10.1016/j.contraception.2021.01.010. Epub 2021 Jan 30.
We calculated the prevalence of contraindications to progestin-only pills (POPs) among reproductive age women to evaluate the safety of over the counter provision.
This descriptive study queried a multi-institution US database to identify women ages 10 to 45 presenting for preventive care, and a subset of this initial cohort also presenting for contraceptive services, to estimate the prevalence of contraindications to POPs using diagnosis and procedure codes.
Among 813,888 females seeking preventive care between 2009 and 2015, 4.36% had a condition associated with a potential risk or unacceptable risk for initiation of POPs, compared to 2.29% of the 71,216 women seeking both preventive care and contraceptive services. Current breast cancer, the only condition classified as an unacceptable risk for initiation, was listed as a diagnosis for 2.67% and 0.57% in each respective group.
The prevalence of contraindications to POPs among reproductive age women is low. This finding supports the relative safety of an over the counter progestin-only contraceptive pill.
This analysis provides support for the safety of over the counter access to progestin-only contraceptive pills.
我们计算了孕激素避孕药（POP）在育龄妇女中的禁忌证发生率，以评估非处方供应的安全性。
本描述性研究查询了美国多机构数据库，以确定年龄在 10 至 45 岁之间因预防保健就诊的女性，并对该初始队列中的一部分也因避孕服务就诊的女性进行了亚组分析，以使用诊断和程序代码估计 POP 禁忌证的发生率。
在 2009 年至 2015 年间寻求预防保健的 813888 名女性中，有 4.36%的女性存在与 POP 起始相关的潜在风险或不可接受风险的疾病，而在同时寻求预防保健和避孕服务的 71216 名女性中，这一比例为 2.29%。当前乳腺癌是唯一被归类为起始不可接受风险的疾病，在每个相应组中，该疾病的诊断比例分别为 2.67%和 0.57%。
育龄妇女中 POP 禁忌证的发生率较低。这一发现支持了非处方孕激素避孕药的相对安全性。
这项分析为孕激素避孕药的非处方获得提供了安全性支持。
